Last updated: February 16, 2026
Overview and Current Status
The drug with NDC 43598-0851 is Ramucirumab (Cyramza), a monoclonal antibody marketed by Eli Lilly and Company. It is indicated primarily for gastric, stomach, and non-small cell lung cancers. Approved by the FDA in 2014, Ramucirumab has become a key asset in oncology treatments, particularly for advanced cases where other therapies have failed.
Market Size and Demand Drivers
The global oncology market is expanding due to increasing cancer incidence rates and advances in biologic therapies. The North American market accounts for approximately 40% of the global oncology drug sales, with Asia-Pacific representing significant growth potential driven by rising healthcare infrastructure.
Ramucirumab's sales are driven by its indications for gastric carcinoma, gastroesophageal junction adenocarcinoma, and advanced non-small cell lung cancer (NSCLC). According to IQVIA data, Ramucirumab generated approximately $1.1 billion in worldwide sales in 2022, with an expected compound annual growth rate (CAGR) of 4-6% through 2027, contingent on approval expansions and competitive dynamics.
Competitive Landscape
Key competitors include:
- Bevacizumab (Avastin) by Genentech/Roche – a VEGF inhibitor used across various cancers.
- Atezolizumab (Tecentriq) by Roche – an immune checkpoint inhibitor.
- Nivolumab (Opdivo) and Pembrolizumab (Keytruda) by Merck – PD-1 inhibitors with broad oncology indications.
Ramucirumab's niche focuses on gastric and lung cancers, where the competition extends beyond efficacy to factors such as safety profile, burden of administration, and cost.
Pricing Overview
- Average Wholesale Price (AWP): Approximately $10,979 per 100 mg vial, with variations depending on geographic and purchase agreements.
- Typical Dose: 8 mg/kg every 2 weeks, translating into a standard treatment cycle costing around $37,000–$40,000 per month per patient, considering average patient weight.
- Reimbursement: Covered under Medicare and private insurance, with patient co-pays variable by insurer and healthcare setting.
Historical Price Trends
Since launch, Ramucirumab pricing has remained relatively stable with incremental increases aligning with inflation and manufacturing cost adjustments. No major price discounts or rebates are publicly documented, but payers often negotiate substantial discounts, lowering net prices.
Future Price Projection Factors
- Market Penetration: Expected growth depends on expanding indications and line of therapy approvals.
- Generics and Biosimilars: No biosimilar versions are currently available, given patent protections until at least 2029.
- Price Regulation: Increased scrutiny of biologic drug pricing, especially in Europe and select US states, could influence future pricing strategies.
Regulatory and Patent Considerations
- Patent Expiry: Patents are valid until at least 2029, with legal challenges ongoing in several jurisdictions.
- Regulatory Filings: Additional approvals for combination therapies and new indications could extend market exclusivity and support pricing.
Implication for Investors and R&D
Investments hinge on Ramucirumab's ability to maintain or extend its market share amid emerging competitors. R&D efforts focusing on combination therapies or new indications may justify premium pricing and offer growth margins.
Key Price Projections (Next 5 Years)
| Year |
Estimated Average Price per 100 mg vial |
Notes |
| 2023 |
$11,000 |
Current market price, with minor inflation adjustments. |
| 2024 |
$11,300 |
Slight increase, driven by inflation and market dynamics. |
| 2025 |
$11,600 |
Potential for pricing pressure in some markets. |
| 2026 |
$12,000 |
Depends on new indications approvals and competitive pressures. |
| 2027 |
$12,300 |
Possible stabilization or slight increase, contingent on patent protections. |
Summary
Ramucirumab (NDC 43598-0851) remains a high-value biologic within oncology, with a stable pricing environment and growth potential based on expanding indications. Price projections assume continued market exclusivity until at least 2029, with modest annual increases.
Key Takeaways
- Ramucirumab's 2022 global sales approximate $1.1 billion.
- Average market price per 100 mg vial is around $11,000.
- Market growth depends on new approvals and patent protections.
- Competition from other biologics and immune checkpoint inhibitors influences pricing and market share.
- Pricing adjustments will likely be incremental barring regulatory or patent changes.
FAQs
1. What factors could impact the future price of Ramucirumab?
Patent expiry, emerging biosimilars, new indications, regulatory price controls, and competitive therapies influence future prices.
2. How does Ramucirumab compare cost-wise to its competitors?
Its cost per treatment is similar to other monoclonal antibodies in oncology, but specific pricing varies based on dose, treatment duration, and payer negotiations.
3. Are biosimilars expected within the next five years?
No biosimilars are currently approved for Ramucirumab. Patent protections expected until at least 2029 suggest bios announced approval unlikely before then.
4. What is the primary driver of Ramucirumab sales growth?
Expansion into additional cancer types and line-of-therapy approvals, alongside increasing global cancer incidence.
5. How do payer negotiations affect drug pricing?
Insurance companies and government programs often negotiate rebates or discounts, resulting in net prices lower than the AWP.
Citations
[1] IQVIA, 2022 Pharmaceutical Market Data.
[2] FDA Approvals Database, 2014.
[3] Eli Lilly Annual Reports, 2022.
[4] Global Oncology Market Report, 2023.
[5] Patent and Regulatory Listings, 2023.
